Portfolio Rapha Capital Management

3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors

By Kevin SlawinApril 1, 2019February 4th, 2021No Comments

3DBio Therapeutics
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
April 1, 2019

Previous PostPoseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round
Next PostAsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions